Fractyl Health To Present Poster Of New Preclinical Data From Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform At ADA 85th Scientific Sessions

Fractyl Health, Inc. (NASDAQ:GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced it will present a poster of new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform at the American Diabetes Association's (ADA) 85th Scientific Sessions being held June 20-23, 2025, in Chicago, Illinois.

Poster Presentation Details

Session Title: Late Breaking Poster Session

Abstract Title: Single-Dose GLP-1–Based Pancreatic Gene Therapy Prevents Obesity and Diabetes in High-Fat–Fed Mice

Poster Number: 1970-LB

Date and Time: Sunday, June 22, 2025, 12:30 p.m. – 1:30 p.m.

Location: Poster Hall (Hall F1, Level 3)